A Study Evaluating Enzalutamide Pharmacokinetics and Pharmacodynamics, and Related Changes After Drug Switch
Status:
Completed
Trial end date:
2019-08-28
Target enrollment:
Participant gender:
Summary
This is a study for evaluating enzalutamide pharmacokinetics and pharmacodynamics, and
related changes after drug switch in Chinese patients with metastatic castration-resistant
prostate cancer. The study primary objective is to evaluate the pharmacokinetic
characteristics of enzalutamide in Chinese patients with mCRPC.
Phase:
Phase 1
Details
Lead Sponsor:
Hinova Pharmaceuticals Inc. Sichuan Haisco Pharmaceutical Group Co., Ltd.